Update information

June 2024

The wording of the recommendation describing the commercial arrangement (see section 1.1), and in section 2.4, has been updated to include procurement information about tocilizumab biosimilars.

Minor changes since publication

June 2021: Recommendation 1.3 added on equality when using the disease activity score.

January 2016: The first bullet point of recommendation 1.1 has been updated by the recommendations in the NICE technology appraisal guidance on adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed.

February 2014: Implementation section updated to clarify that tocilizumab is recommended as an option for treating rheumatoid arthritis.

ISBN: 978-1-4731-6168-9